Jump to content
IndiaDivine.org

Smuggling Hope

Rate this topic


Guest guest

Recommended Posts

Guest guest

http://www.motherjones.com/news/feature/2004/03/02_403.html

 

Smuggling Hope

 

Her father was dying, and the drug company wanted $47,000 for his medication. So

she did what any daughter would do: She became a liar and a fraud.

By Julia Whitty

 

March/April 2004 Issue

 

Two years ago my father phoned to tell me that a new prescription from his

oncologist—what amounted to his last line of defense against the cancer he had

been battling for years—was beyond his reach financially. His previous treatment

had worked far better for him than for the average patient with his condition,

but its efficacy had dwindled during a long sabbatical from drug treatment,

during which he underwent a major surgery. Now faced with either an old drug

regimen that no longer worked or a prohibitively expensive new drug, his only

realistic option, he told me, was to forgo further medication. In other words,

he was prepared to die. I had a hard time accepting this. With his engineer's

mind, my father had managed to navigate his way through the murky realms of

conflicting treatments and doctors' opinions, keeping himself alive far beyond

his original prognosis. At the time of his call to me, he was fit and strong,

and his cancer—which had been stabilized by the previous

treatments—was currently progressing at an almost imperceptible rate. Yet I

knew what he probably did not: that his end from this particular disease would

be, in the words of an oncologist friend, " one of the worst deaths possible. " If

there was any way aroundthis, any way at all to spare or delay the suffering

that lay ahead, I was prepared to try it.

 

Two years later, and a few months after my father died, my mother took the train

cross-country to visit me in California. Somewhere in Nebraska—in the course of

a 10-hour Amtrak delay—Congress passed the Medicare drug bill. During the dreary

wait for railroad repairs, a fellow passenger asked my mother what she thought

of this bill. She didn't like it, she said, at which point the passenger

confessed to being an employee of AARP, and added that the AARP employees didn't

like it any better themselves. The consensus-of-two was that this was a welfare

plan not for the elderly or the sick, but for the phenomenally healthy

pharmaceutical industry.

 

Somehow, in hearing my mother tell this story, the saga of my father's

misadventures in the American health care system came full circle. Triggered by

his call two years earlier, I had become something I had never imagined—a

smuggler and a fraud—in pursuit of that which my father had never conceived of

upon retirement 12 years earlier: a prescription costing so much that it would

justify the purchase of an expensive supplemental drug-insurance plan. My family

of immigrants, once eager for a piece of the buoyant American economy, found

ourselves wondering if we would have fared better in virtually any other

industrialized country on earth, where the impossible choice between bankrupting

ourselves, breaking the law, or forgoing lifesaving treatments did not exist.

 

" I don't know why Americans resent paying taxes, " my father often said during my

childhood. " They don't seem to understand that taxes provide them with things

they need. " By the end of his life, I think he resented taxes himself,

perceiving that too much of the wages of the middle class was spent on corporate

entitlement programs, including those aiding the $235 billion-a-year global

pharmaceutical industry. By the time of his death, the business of prescription

drugs had become the most profitable industry in America, with a staggering

campaign war chest of $29.4 million in 2002—enough funds to employ in excess of

600 lobbyists, more than one for every member of Congress, and enough power to

make elections and legislation in its own image.

 

The new drug my father's oncologist was prescribing for him was well known to me

(for legal reasons, I will omit its name and the manufacturer's name), for it

had a fearsome reputation from decades earlier. How expensive could this drug

be, I wondered, when all the research and development had been done 40 years

ago, at a fraction of the modern costs? A hell of a lot, was the answer. I still

don't know why. But in my father's case, it was about $47,000 a year, with the

potential to triple, based on his clinical response, to $141,000 a year. At this

rate, in seven years, he could conceivably have spent a million dollars.

Although he had profited from decades of employment in North America, he had not

profited well enough to pay for that, and he was realistic enough about his

medical future to resist becoming " spent out " —the current jargon for those who

have anted up all in pursuit of staying alive—leaving him and my mother

financially ruined (at which point, ironically, they would

have been eligible for free drugs).

 

Like millions of frustrated others, I turned to the Internet, hoping to find

some way of acquiring what my father needed. There was a whole cadre of us out

there, I learned, seeking drugs for ill parents, or spouses, or children. There

were those looking, and those giving—including the survivors of the deceased,

who were willing to pass along the remnants of no-longer-needed prescriptions.

Like addicts, we identified ourselves by first name only, and our missives were

sad and apologetic. " I am sorry, " wrote a fellow sufferer, who had originally

thought he could help me with my father's drug. " I looked everywhere I could

think of and couldn't find any _____. It must have been thrown away or used, I

guess. My dad tossed a ton of stuff. I think I was too disturbed by my mom's

death to rigorously look through it at the time. I am very sorry. "

 

Upon my father's retirement in 1991, he automatically became covered by Medicare

and chose to purchase supplemental AARP hospitalization insurance. He decided

against the supplemental prescription-drug insurance because, as he later told

me, he could not conceive of any drug costing enough to justify paying $2,400 a

year for it. For me, one of the more painful aspects of our predicament was the

fact that my father, a son of the Depression and of World War II, prided himself

on always being prepared for the bleakest prospects the future might deliver.

But not even his darkest imaginings could prepare him for the breathtaking

ascent in the price of drugs—costing Americans $213.4 billion in 2003—which he

regarded as a personal failure of his preparedness skills.

 

Because more than a third of Medicare patients have no prescription-drug

benefits, Congress enacted the Medicare drug bill last December, at an estimated

cost of $400 billion over the next decade. In the weeks following its passage,

it became a matter of morbid curiosity to me to assess whether or not the new

law would have solved my father's problems. If he had survived, here is what he

might have looked forward to: After paying a $420 annual premium, plus a $250

annual deductible, the government would have covered 75 percent of his

prescription costs up to $2,250; he would then have been responsible for all

payments up to $5,100, at which time the government's catastrophic aid would

have kicked in, paying 95 percent of his drug expenses. So I estimate that he

would have been responsible for $6,115 of his $47,000 cancer drug. Would he have

paid that much? I can't say for sure. Locked into a fixed income that was in

decline along with the stock market, he might have decided against

it.

 

Generally speaking, if my father had been a very low-income senior, he might

have fared better under the new plan, unless he lived in a state where Medicaid

had been paying for prescriptions without charging him deductibles or premiums.

If he had been a middle-income senior with modest drug costs, he would probably

have fared no better and might have ended up paying more in annual premiums than

his drugs cost. If his expenditures had fallen into the " doughnut hole, " between

$2,250 and $5,100, he would have found little relief. Ironically, his worst-case

scenario under the new plan would have been a complete reversal of what had been

the best-case scenario, i.e., a retiree who still enjoys employer-paid health

coverage. Such people were once the lucky few; but under the new legislation,

all 3.8 million of them stand to lose that coverage entirely. And those whose

new Medicare drug bene-fits will be provided via privately run programs could

find themselves denied expen- sive drugs,

say, ones that cost $47,000.

 

So who will fare well? Doctors and hospitals will get a boost, because a

scheduled cut in their Medicare payments has been eliminated. The insurance

companies will receive new subsidies designed to encourage them to cover seniors

and the disabled. But the really big winners will be the drug companies, who are

estimated to see a 9 percent increase in sales, or $13 billion in additional

profits per year.

 

 

 

After a lot of fruitless trolling, my Internet searches eventually led me to a

pharmaceutical company overseas that made the same drug my father needed under a

different brand name for roughly $1,200 a year—absurdly cheaper than the $47,000

a year the American company was demanding (and roughly one-fifth what my father

would have paid under the new Medicare bill). What would you do? Well, I did it

too—and can now add drug smuggling to the dubious accomplishments on my résumé.

 

My family was not alone. For years, patients with AIDS or cancer have been

buying drugs from Mexico, either because these drugs are not available in the

United States, or because they are available more cheaply south of the border.

More recently, Americans have begun wandering north. The first organized

busloads of drug-buying American seniors crossed into Canada in the mid-1990s,

and currently, between 1 and 2 million Americans of all ages buy Canadian drugs

via the Internet. It's easy to see why. Cholesterol-lowering Lipitor costs $127

in the United States, $60 in Canada; the anti-arthritis drug Celebrex costs $106

here, $41 there.

 

Having spent much of my adult life traveling and working overseas, and having

many personal contacts in foreign countries, I had the means to procure a doctor

in the country that manufactured the drug, get a prescription, fill it at a

pharmacy there, and bring it home. We had concerns, though. I worried that U.S.

Customs, or even airport security, might ask what I was doing with so many

foil-wrapped packets of pills. To offset this possibility, I opened all the

packets and emptied their contents into prescription bottles I had brought

along. Yet this solution raised another concern: the memory of a news story a

few years ago about an American woman trapped in a hellhole of an overseas jail

because she had prescription drugs in mismatched bottles. Luckily, when

smuggling my father's prescription, no one ever stopped or questioned me, and

aside from some sweaty moments feeling like a drug runner (and hoping I did not

look like one), the process went smoothly. Over time I was also able

to use non-American friends as coyotes to smuggle refills.

 

Within a couple of months, my family's other concern—that the foreign drug would

be ineffective—proved groundless. Scans showed my father's tumors, which had

previously been advancing, were in retreat; his doctors were delighted with his

response and even more tickled to learn how he had overcome the impossible

limitations of the American health care system.

 

A few months later I discovered that we might be able to import the drug

quasi-legally into the country. " We have sent ______ to the USA many times, "

wrote my contact at the overseas pharmaceutical company. " We have contacted DHL

and they advised that, if the doctor clearly specifies the doses in the

prescription, they think there will be no problem in USA customs. "

 

Filled with optimism at reclaiming the status of law-abiding citizens, we sent

off the money and the order. But the process took longer than anticipated. My

father's current supply of the drug was running out, and we didn't know if an

interruption in treatment would enable the cancer to renew its attack. We

worried. As weeks passed and the shipment still had not arrived, we worried some

more, and then split his daily dose in half, trying to eke out his supply. When

the delay continued, we halved it again. Eventually, we heard from U.S. Customs

that the package was being held by the Food and Drug Administration, which was

not convinced of the legality of this import or of my father's need for this

foreign drug. We provided a slew of hastily improvised reasons why this formula

was better than the American formula, pointedly avoiding the only real

reason—because the FDA had advised us it was not a valid one—which was that the

foreign version was monumentally cheaper, and the only one we

could afford. The FDA was not swayed.

 

" We cannot vouch for the efficacy of this foreign drug, " my FDA case officer

told me, as I struggled to liberate my father's shipment. I said that I wasn't

asking them to vouch for it, because I already knew that it worked, and would be

happy to send my father's scans as proof.

 

The FDA likes to cite the dangers of buying drugs from abroad (even drugs made

in the United States and sold in Canada), and it is true that there's an

alarming rise in counterfeit drugs—those made with fake ingredients or diluted

doses of the real ingredients. But buying from American pharmacies is risky too.

Recently, an AIDS patient in San Francisco discovered that his prescription for

Serostim, bought through a CVS pharmacy, was actually a fertility drug. Last

August, the FDA pulled 1.8 million doses of counterfeit Lipitor from American

pharmacies, but not, it admits, before some was used. In December, Eli Lilly

halted sales to five U.S. drug wholesalers after a counterfeit version of a drug

(which Lilly would not name) was purchased. Also that month, federal agents

seized some 1 million pills of counterfeit Celebrex, Bextra, and Allegra from a

Florida warehouse.

 

So are American drugs any safer than Canadian? To date, the FDA cannot name a

single American who has been injured or killed by prescriptions bought from

licensed Canadian pharmacies.

 

Under the new Medicare drug bill, Americans are now expressly forbidden from

importing U.S.-made drugs available more cheaply from overseas. Here's how it

works: I can go to Europe and buy their wine for less or go to Asia and buy

their clothes for less; American corporations can buy their raw materials for

less from overseas, or they can move their operations abroad in order to hire

cheaper labor or management. But in a mind-boggling reversal of the American

principle of supply and demand, I cannot purchase cheaper drugs and bring them

home.

 

And try as I might, I cannot imagine who is benefiting from such laws other than

the U.S. drug companies. The regulations did not protect my father—who was

desperately seeking his next dose—and were conceivably killing him. When his

supply finally ran dry, we tided him over with a diluted dose from the leftover

prescription of a dead person. When the FDA threatened to destroy his shipment,

I contacted my senators and my representative, asking for help. Dianne

Feinstein's and Lynn Woolsey's people would not or could not give any. But

Barbara Boxer's folks did, inspiringly, and within 48 hours of my request they

had sprung my father's package from the clutches of the FDA, just in time for

the Fourth of July.

 

 

 

In another bizarre aspect of the new Medicare drug bill, Congress has forsworn

its ability to negotiate lower drug prices—because this would amount to

government price controls, say some lawmakers. Never mind that by purchasing in

such gigantic quantities the government could bargain for a better price—one of

the working tenets of capitalism. Never mind that it already does negotiate for

lower prices through the Department of Veterans Affairs. As things currently

stand, the costs of best-selling drugs in America are 77 percent higher than in

Canada and Europe (where prices are tightly regulated), enabling the drug

companies to milk 66 to 75 percent of their profits from American consumers, who

in essence subsidize cheap pills for Canadians and Europeans. Yet despite this

unwitting generosity, I cannot legally visit those countries and reimport what

my subsidy sold them on the cheap in the first place.

 

Defenders of this aspect of the bill claim that high prices are needed to

counteract the enormous costs of research and development of new drugs, the

much-touted $800 million-plus per new drug, spent over 10 to 15 years of

testing. But is this where the pharmaceutical industry really spends its

profits—that 30 to 40 percent annual return on equity that has made it the most

profitable business on earth three of the last five years? Apparently not. In

2002, the nine top publicly traded U.S. companies that market popular drugs to

seniors spent $45.4 billion on advertising (restricted in Canada and Europe), on

marketing (including billions' worth of free drug samples to physicians), and on

administration. Meanwhile, they spent only $19.1 billion on R & D, much of which

is on testing new uses (and thus new profit centers) for already approved drugs.

 

The marketing blitz works. Americans currently buy more than twice the number of

prescriptions as Europeans, and sales of the 50 most heavily advertised drugs

jumped 24.6 percent between 1999 and 2000. To offset the costs of all this

advertising, the drug companies now practice rampant price inflation in the

United States, escalating the retail costs of drugs each year by more than three

times that of actual inflation.

 

Although the federal government appears unwilling to address this problem, some

states are responding. In February 2003, New York sued GlaxoSmithKline,

Pharmacia Corp., and Aventis for illegally inflating what the state and its

Medicare recipients paid for prescription drugs through an elaborate pricing

scam. Minnesota is currently suing the pharmaceutical companies (which state

officials call " the other drug cartel " ), because 85 percent of new drug R & D is

performed by the National Institutes of Health and tax-funded university labs.

Both suits are pending.

 

Meanwhile, the costs of generic drugs, those once trusty alternatives, are

rising nearly twice as fast as brand-name drugs, due in part to the

consolidation of the generic-drug industry. So even thrifty patients are joining

the ranks of the one-fifth of Americans who currently cannot afford what their

doctors prescribe and are forced to skip doses, or entire prescriptions, in

order to make ends meet.

 

The pipeline for my father's drug worked well for the remainder of 2002. But at

the end of that year, a package foundered on the shores of the FDA, and not even

Barbara Boxer's people could wrestle it free. The government was cracking down

on imports, and although my contact officer at the FDA was sympathetic, she

nixed the few remaining loopholes almost as soon as she thought them through. In

the end, she suggested that I try the prescription-drug-assistance program of

the U.S. pharmaceutical company that made the drug my father needed.

 

We had already tried this—back in the beginning—following the advice of one of

my father's doctors, who suggested that we need not be " entirely truthful " as to

his financial situation on the application. So we lied, but only a little, and

were rejected. Now, a year later, we would try again, and I was prepared to be

utterly ruthless this time. It did not feel like stealing because, in all

honesty, I didn't feel bad about milking a company so willing to do the same to

us.

 

When I queried a representative at the prescription-drug-assistance program as

to whether my father needed to be indigent to be accepted, she said no, not

indigent. Then, miraculously, she coughed up one small brilliant truth, which in

the ensuing silence I knew she was already regretting. " We don't actually check

anything you say on the application, " she told me. It was like being given a key

to the City of Health. We submitted the new application for my father, the

almost-indigent, and were accepted. The new drugs began arriving free from our

former $47,000-a-year nemesis.

 

In retrospect, the whole process of getting this drug for my father—although

difficult and painful—was easier for my family than it would be for many others.

We were willing and financially able to travel overseas, to ask help of (or

harass) our elected officials, to pour our collective energy into pioneering a

solution. At the beginning of our search, my father had already spent his

retirement years on what I estimate to be the equivalent of a full-time job

managing his own health care—either researching it, administrating it, or

undergoing it. I can't imagine this was what he had envisioned for his golden

years, but he did the work stoically, employing the same problem-solving talents

he had used as a private contractor on classified Defense projects for the U.S.

government. But by the time his cancer drugs began arriving free of charge, his

health was failing. In the last months of his life, he could no longer negotiate

a phone call to wrangle with drug companies or government

agencies. He could not have managed finding alternate sources of the drug. If

he had been like millions of others without the strength to help themselves, or

without resourceful helpers, he would have died earlier. As many must do.

 

A couple of months after his free drugs arrived, my father entered the hospital

for the last time. His drugs came with him and were administered until nearly

the end. Amazingly, his prescription was still working, was still holding the

cancer in check. The drug's initial promise had proved well worth all the

subsequent troubles and anxieties, buying him another year of life at least, so

that he did not die from his cancer, the worst possible death, as I had feared.

Instead, his heart quit, possibly due to problems with other treatments

attendant to his condition. Or maybe he was worried about the way his full-time

job managing his health care had become ours. At any rate, he was tired. He let

us go.

 

Will the medicare drug bill help? Maybe. But I have absolutely no doubt that the

smuggling will go on. The bus trips to Tijuana and Toronto will continue to

deliver the desperate who have no alternative but to pay $14 for the Tamoxifen

that would cost them $60 at home. The flights around the world to cheap

pharmacies and drug companies will not disappear simply because the government

will, beginning in 2006, pay 75 percent of drug costs for seniors spending less

than $2,250 a year. One-quarter of Americans under the age of 65 have no

prescription-drug benefits whatsoever, and they will remain highly motivated to

search elsewhere.

 

Only when the prices of drugs fall into some compliance with the rest of the

world will the black market subside. I wonder if the pharmaceutical giants ever

calculate what would happen to their profits if they lowered their prices and

wooed back all the lost consumers like my father who are fleeing to the far ends

of the earth. Or if, by making drugs affordable, they might not attract all

those who simply throw away their prescription slips because they cannot afford

the drugs—or those who stagger their doses for the sake of economy.

 

In response to the high prices, a few states and municipalities are beginning to

flex their bargain-hunting muscles too. Springfield, Massachusetts, is

reimporting drugs from Canada for its city employees. Burlington, Vermont, plans

to follow. Boston announced it will do so for 7,000 employees and retirees,

saving an estimated $1 million a year. New Hampshire plans to reimport for its

prison population and Medicaid patients. Initially, the U.S. government seemed

to take this trend in stride. But last December, when Illinois announced its

plan to save $91 million by reimportation, Governor Blagojevich was warned by

the feds that such a move would be illegal. " Our law is very specific, " said a

government spokesperson. " It's not 'will not.' It's 'cannot.' " And drug

companies are also being aggressive: GlaxoSmithKline warned Canadian pharmacies

to stop selling to Americans or their supplies would be shut down.

 

In the wake of this anarchy, a few in Congress are re-examining a bill sponsored

by Rep. Gil Gutknecht of Minnesota that would allow reimportation from

FDA-approved facilities in 25 industrialized countries and employ technology to

prevent counterfeiting. But if the pharmaceutical industry gets its way, such

legislation will die—turning an increasing number of sick and desperate

Americans into outlaws, or forcing them into early graves.

 

Meanwhile, my contact information floats in cyberspace, and I continue to get

requests from the others out there with first names only who are looking for the

same drug my father once used. I am more than happy to tell them what I know,

how to work the system, how to break the law. " Thanks so much! " one contact

responded. " (And thank goodness for email and the wonderful network of caring

people such as you.) This is terrific information! Until the FDA comes to its

senses, it seems that those overseas are truly our friends. "

 

Others write to me of their struggles when the loved ones they fought so hard to

save die. " My mom was very religious, so I read the Bible. But sometimes nothing

seems to help. My mom was a kind of optimistic, cheerful type person. So it is

going to be hard to find something to compensate for that, as well as her caring

and love for me. I mean, you don't find that anywhere else in the world. "

 

No, you don't. And that's why the pipeline won't close until the cheap drugs

come home again.

 

Julia Whitty makes nature documentaries and writes short stories, novels, and

nonfiction. For her previous Mother Jones article, " All the Disappearing

Islands " (July/August 2003), she reported from the low-lying Pacific nation of

Tuvalu, whose existence is threatened by global warming.

 

What We Pay

 

Americans taking prescription drugs -- even the most common, highly-prescribed

drugs -- uniformly pay far more per pill than their Canadian neighbors.

 

Late last year, surrounded by a cadre of Republican leaders from Congress,

President Bush signed into law the Medicare drug bill. The president heaped

praise on the measure, calling it a reflection of the administration's

priorities.

 

" Some older Americans spend much of their Social Security checks just on their

medications. Some cut down on the dosage, to make a bottle of pills last longer.

Elderly Americans should not have to live with those kinds of fears and hard

choices, " Bush declared. But at no point during his comments did Bush bother to

mention the fundamental reason so many seniors have struggled to pay for

prescription drugs: per-pill costs.

 

Compared to the citizens of just about every other industrialized nation,

Americans pay a premium for just about every prescription they fill. And those

price hikes aren't limited to the most expensive or least common drugs.

MotherJones.com has reviewed the average costs for 18 frequently-precribed drugs

in the U.S. and Canaada. The results: From arthritis treatments to

antidepressants, hypertension medications to menopause drugs, Americans pay

more.

 

 

 

 

 

 

 

 

 

Small Business $15K Web Design Giveaway - Enter today

 

 

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...